AMPH
Amphastar Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 77 | -4 | 22.11M | $440.50M | +3 | −7 |
| Q1 2026 | 84 | -10 | 23.72M | $457.46M | +4 | −14 |
| Q4 2025 | 94 | -1 | 25.83M | $677.54M | n/a | −1 |
| Q3 2025 | 19 | 0 | 15.63M | $416.60M | n/a | n/a |
| Q2 2025 | 16 | +1 | 14.08M | $323.35M | +1 | n/a |
| Q1 2025 | 12 | -1 | 5.84M | $169.25M | n/a | −1 |
| Q4 2024 | 13 | 0 | 4.91M | $182.39M | n/a | n/a |
| Q3 2024 | 12 | +2 | 3.20M | $155.33M | +2 | n/a |
| Q2 2024 | 10 | n/a | 3.67M | $146.92M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 906.35K | n/a | $36.26M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Millennium Management ✦ | 738.75K | n/a | $29.55M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 583.91K | n/a | $23.36M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Renaissance Technologies ✦ | 537.70K | n/a | $21.51M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 263.15K | n/a | $10.53M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 6 | Point72 Asset Management ✦ | 235.84K | n/a | $9.43M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Marshall Wace ✦ | 227.13K | n/a | $9.09M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 96.43K | n/a | $3.86M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 55.80K | n/a | $2.23M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 10 | Gotham Asset Management ✦ | 27.68K | n/a | $1.11M | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 212 holders, 31.98M shares, $604.53M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 4.14K sh · $103,475
Officer · 10.00K sh · $239,404
Officer · 3.19K sh · $75,306
Director · 7.97K sh · $161,852
Officer, Director · 8.18K sh · $183,886
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology